Semaglutide vs Tirzepatide vs Retatrutide UK: 3 GLP-1 Peptides — The Essential Research Guide 2026
A Phase 2 trial published in the New England Journal of Medicine (2023) reported retatrutide achieving up to 24.2% mean body weight reduction at 48 weeks — a figure that outpaced both semaglutide (~14.9%, STEP 1) and tirzepatide (~22.5%, SURMOUNT-1) in comparable non-diabetic populations. The GLP-1 receptor agonist class has fundamentally redefined metabolic research, but three structurally distinct compounds now occupy very different positions on the efficacy spectrum. This guide unpacks the mechanism, clinical data, and sourcing considerations for UK researchers working across all three.
Quick Takeaways
| Key Point | What It Means for Research |
|---|---|
| Retatrutide is a triple agonist (GLP-1 + GIP + glucagon) | Broader metabolic pathway engagement than either monotherapy or dual agonist approaches |
| Semaglutide remains the most studied GLP-1R agonist | Largest published evidence base; STEP 1–5 programme provides robust comparative benchmarks |
| Tirzepatide (dual GLP-1/GIP) outperformed semaglutide in SURMOUNT-1 | Adding GIP agonism produced ~7.6 percentage point additional weight reduction vs semaglutide benchmarks |
| Retatrutide glucagon co-agonism drives additional energy expenditure | Hepatic fat reduction and thermogenic effects not observed with GLP-1 or GIP alone |
| Phase 2 retatrutide data (NEJM 2023) is non-diabetic population only | T2D data from TRANSCEND programme (2024–25) shows additional glycaemic control signals |
| UK-Peptides publicly states no third-party lab testing on their blog | For reproducible research, batch-specific CoA from an independent HPLC lab is essential |
| All three compounds are research-use only in the UK | None are licensed for self-administration; supply for laboratory and preclinical research is lawful |
| Purity standard matters: ≥99% HPLC verified is the minimum for viable research | Sub-99% samples introduce confounding variables; always request a batch-specific certificate |
Semaglutide vs Tirzepatide vs Retatrutide UK: How Each Compound Works
Semaglutide — GLP-1 Receptor Monotherapy
Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) with approximately 94% structural homology to endogenous GLP-1. Its extended half-life (~7 days) results from albumin binding via a C-18 fatty diacid linker, enabling once-weekly dosing protocols in research settings.
The compound’s primary actions are: (1) glucose-dependent insulin secretion stimulation, (2) glucagon suppression during hyperglycaemia, (3) delayed gastric emptying, and (4) central appetite suppression via hypothalamic GLP-1 receptors. In preclinical rodent models, semaglutide has been studied across neuroinflammatory, hepatic, and cardiovascular contexts beyond its established metabolic applications.
When comparing semaglutide vs tirzepatide vs retatrutide UK research profiles, semaglutide offers the longest evidence base — over a decade of published preclinical and clinical data. Arma Peptides supplies this as SLIMERIX™ 5MG — lyophilized, ≥99% HPLC purity, batch CoA included.
Tirzepatide — Dual GLP-1 / GIP Agonist
Tirzepatide is a single synthetic peptide designed to co-activate both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. This dual incretin approach amplifies insulin secretion beyond GLP-1 stimulation alone, while GIP receptor agonism appears to modulate adipose tissue biology and potentially reduce the nausea burden associated with GLP-1 monotherapy.
Research interest has expanded into tirzepatide’s effects on beta-cell function, lipid metabolism, and hepatic steatosis. The SURMOUNT-1 trial (Jastreboff et al., 2022) demonstrated 22.5% mean weight reduction at 72 weeks at the 15 mg dose in non-diabetic adults with obesity. In the semaglutide vs tirzepatide vs retatrutide UK comparison, tirzepatide sits in the middle of the efficacy spectrum — outperforming semaglutide, but narrowly behind retatrutide on absolute weight reduction data. Arma Peptides supplies this as ZONJERO 30MG at £130 — the highest dose format available from a UK-verified supplier.
Retatrutide — Triple GLP-1 / GIP / Glucagon Agonist
Retatrutide (LY3437943, Eli Lilly) represents the next generation of metabolic research compounds. It co-activates three G-protein–coupled receptors simultaneously: GLP-1R, GIPR, and the glucagon receptor (GCGR). The addition of glucagon receptor agonism is mechanistically significant — glucagon drives hepatic glucose output and thermogenesis, effects that are traditionally considered undesirable in isolation, but when balanced against GLP-1/GIP-mediated insulin secretion, appear to produce synergistic energy expenditure without hyperglycaemia.
The Phase 2 NEJM 2023 trial (Jastreboff et al.) documented 24.2% mean weight reduction at 48 weeks with the 12 mg dose in non-diabetic adults — the highest efficacy signal from any single compound in a randomised controlled trial to date. The full mechanistic rationale behind this result is explained in the NEJM Phase 2 retatrutide trial publication.
For UK researchers evaluating semaglutide vs tirzepatide vs retatrutide UK sourcing options, retatrutide is the most potent and most recently characterised of the three. Arma Peptides supplies this as RETATRUTIDE REVYTAL 30MG — the highest dose available from any UK supplier at £130, with third-party HPLC verification per batch.
Clinical Trial Data: Semaglutide vs Tirzepatide vs Retatrutide UK Research Benchmarks
Weight Reduction Benchmarks
| Compound | Trial | Population | Duration | Peak Mean Weight Reduction |
|---|---|---|---|---|
| Semaglutide 2.4 mg | STEP 1 (Wilding et al., 2021) | Non-diabetic adults with obesity | 68 weeks | ~14.9% |
| Tirzepatide 15 mg | SURMOUNT-1 (Jastreboff et al., 2022) | Non-diabetic adults with obesity | 72 weeks | ~22.5% |
| Retatrutide 12 mg | Phase 2 NEJM (Jastreboff et al., 2023) | Non-diabetic adults with obesity | 48 weeks | ~24.2% |
Important caveat for researchers: These trials are not directly comparable. Duration, titration schedules, baseline BMI ranges, and endpoint definitions differ. The data should be used to understand directional differences in pharmacological potency, not as head-to-head equivalences. A 2024 PMC meta-analysis (SUN-659) concluded that retatrutide demonstrated superior absolute and percentage weight reduction vs tirzepatide, though with a higher frequency of GI adverse events at peak dose. UK researchers comparing semaglutide vs tirzepatide vs retatrutide UK sourcing should note all three are available at ≥99% HPLC purity from Arma Peptides.
Glycaemic Control (T2D Populations)
Semaglutide has the longest approval track record (Ozempic for T2D, 2017; Wegovy for obesity, 2021). Tirzepatide received FDA approval as Mounjaro (2022) and Zepbound (2023). Retatrutide’s TRANSCEND-T2D programme data (2024–25) showed HbA1c reductions of 1.7–2.0% across dose arms at 40 weeks — competitive with best-in-class results from both comparators. For UK researchers designing in-vitro or preclinical metabolic studies, all three compounds represent valid and well-characterised tools with published dose-response curves.
Hepatic Fat Reduction
Liver fat reduction is an emerging research area for all three compounds. Retatrutide’s glucagon component provides a mechanistic basis for greater hepatic lipid clearance — glucagon receptor activation upregulates hepatic fatty acid oxidation pathways. Preliminary Phase 2 data suggest retatrutide may outperform both comparators in NASH/hepatic steatosis research contexts. For researchers studying non-alcoholic fatty liver disease models, this mechanistic distinction has significant protocol design implications.
Side Effect Profiles (Preclinical Context)
All three compounds share a class effect of gastrointestinal adverse events (nausea, emesis, diarrhoea) in mammalian models, attributable to GLP-1R activation in the enteric nervous system and area postrema. Key differences:
| Parameter | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| GI adverse events (clinical) | Moderate (~40% any GI) | Moderate-high (~50% any GI) | High (~60% any GI at 12mg) |
| Heart rate increase | +1–4 bpm | +2–4 bpm | +2–6 bpm (dose-dependent) |
| Lean mass preservation | ~Loss of lean mass reported | Better lean mass retention vs sema | Glucagon component may preserve lean mass; under study |
| Gallbladder effects | Cholelithiasis risk elevated | Similar to semaglutide | Data emerging; likely class effect |
Source All Three Compounds from One Verified UK Supplier
SLIMERIX™ (Semaglutide), ZONJERO (Tirzepatide), and RETATRUTIDE REVYTAL — all ≥99% HPLC purity, third-party CoA per batch. UK dispatch in 1–2 business days.
Browse Full Range Telegram DealsFirst order? Use code FIRST10% at checkout. Free delivery over £200.
UK Supplier Comparison Table
When sourcing GLP-1 class research peptides in the UK, purity verification and batch-level documentation are the critical differentiators. The table below benchmarks key supplier attributes relevant to research reproducibility.
| Supplier | Third-Party HPLC CoA | Batch-Specific CoA | Retatrutide Available | Purity Stated | UK Dispatch |
|---|---|---|---|---|---|
| Arma Peptides ★ Recommended | ✅ Yes — independent lab | ✅ Per batch | ✅ 30MG (highest dose) | ≥99% HPLC | 1–2 business days |
| UK Peptides | ❌ No — self-stated on their own blog | ❌ No | Limited | Unverified | Next day |
| Peptides Lab UK | ✅ Third-party stated | Partial | ✅ Yes | >99% | Next day |
| Tide Labs | ✅ UKAS verified | ✅ Yes | Limited mg format | ≥99% | Same day (before 4pm) |
| XL Peptides | Stated, not independently confirmed | Partial | Limited | >98% | UK stock |
Table compiled from publicly available supplier data, May 2026. UK Peptides’ no-third-party-testing position sourced from their own published blog. Researchers should independently verify all supplier claims before procurement.
Arma Peptides: GLP-1 Research Compound Range
All Arma Peptides compounds are supplied as lyophilized powder in sterile vials, tested to ≥99% HPLC purity with a third-party Certificate of Analysis available at /certificate-of-analysis/. For full product documentation, contact info@armapeptides.com.
≥99% HPLC · 30mg (Highest UK dose)
Batch CoA · UK Dispatch
≥99% HPLC · Lyophilized
Batch CoA · UK Dispatch
View the full metabolic research range at armapeptides.com/shop/. Related reading: Retatrutide Research Guide and How to Choose a Peptide Supplier: 7 Proven Tips.
Sourcing Checklist: Semaglutide vs Tirzepatide vs Retatrutide UK Suppliers
Before placing any order for semaglutide vs tirzepatide vs retatrutide UK research peptides, verify the following with your supplier:
- Third-party Certificate of Analysis (CoA) — not self-certified, issued by an independent HPLC lab
- Batch-specific CoA — generic or single-document CoAs do not confirm per-batch purity
- HPLC purity ≥99% — the minimum for research-grade metabolic peptides
- Lyophilized powder format — protects peptide integrity during storage and transit
- Tracked UK dispatch — particularly for temperature-sensitive compounds
- Mass spectrometry identity confirmation — verifies compound identity beyond purity alone
- Research-use-only legal framing — confirms supplier operates within UK regulatory requirements
- Available documentation on compound-specific storage (e.g. -20°C lyophilized, +4°C reconstituted)
Ready to Source? UK’s Most Verified GLP-1 Research Peptides
Arma Peptides is the only UK supplier offering all three — semaglutide, tirzepatide, and retatrutide — with third-party HPLC CoA per batch. Unlike UK Peptides (who openly admit no third-party testing), every Arma batch is independently verified.
Shop Now Join Telegram for Exclusive DealsFirst order discount: FIRST10% | Free delivery on orders over £200 | 1–2 day tracked UK dispatch
Frequently Asked Questions
What is the difference between semaglutide, tirzepatide, and retatrutide?
Semaglutide is a GLP-1 receptor agonist only. Tirzepatide adds GIP receptor co-agonism (dual incretin). Retatrutide adds a third receptor — the glucagon receptor — making it a triple agonist (GLP-1 + GIP + glucagon). Each additional receptor target adds a distinct metabolic pathway, which is why retatrutide shows the highest weight reduction in clinical data to date.
Is retatrutide stronger than tirzepatide for research purposes?
Based on Phase 2 NEJM data (2023), retatrutide at 12mg achieved approximately 24.2% mean weight reduction vs tirzepatide’s ~22.5% at 72 weeks in comparable non-diabetic populations. The glucagon receptor component drives additional energy expenditure and hepatic fat clearance not available with tirzepatide. For UK researchers, retatrutide is the most potent triple-pathway compound currently available in research grade.
Can I buy semaglutide, tirzepatide or retatrutide legally in the UK?
Yes — for legitimate laboratory and preclinical research purposes, these compounds can be legally purchased from compliant UK research peptide suppliers. They are not licensed for human self-administration. Arma Peptides supplies all three exclusively for research use, with documentation confirming this. Always verify your supplier’s legal compliance and documentation standards before ordering.
What purity should I require for GLP-1 class research peptides?
A minimum of ≥99% HPLC purity is the accepted standard for GLP-1 receptor agonist research. Sub-99% samples introduce impurities that act as confounding variables in receptor binding assays, cell-based studies, and in-vivo models. Always require a batch-specific CoA from an independent third-party laboratory — not a generic supplier certificate. Arma Peptides provides this for every batch.
How does retatrutide’s glucagon receptor agonism affect research design?
Glucagon receptor activation introduces thermogenic and hepatic effects absent from GLP-1 or GIP agonism alone. When designing retatrutide research protocols, researchers should account for potential confounds including elevated heart rate, hepatic glycogenolysis, and altered lipid oxidation pathways. These effects make retatrutide particularly relevant for NAFLD/NASH, thermogenic adipose tissue, and hepatic fat models — but require careful differentiation from GLP-1/GIP-mediated effects in study design.
Does Arma Peptides provide a Certificate of Analysis for GLP-1 peptides?
Yes. Every batch of SLIMERIX™ (semaglutide), ZONJERO (tirzepatide), and RETATRUTIDE REVYTAL is independently HPLC-tested to ≥99% purity with a third-party Certificate of Analysis. Certificates are available at armapeptides.com/certificate-of-analysis/. Unlike UK Peptides — who state on their own blog that they do not use third-party labs — every Arma batch is independently verified before dispatch.
